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TGFb signaling is known to play a central role in tumor
biology, via inducing and/or enhancing tumor cell growth
and differentiation, modulating the extracellular matrix
in the stroma, inducing epithelial to mesenchymal transi-
tion, modulating angiogenesis, and inhibiting immune
surveillance and anti-tumor immunity. Galunisertib is a
pharmacological inhibitor of the TGFb pathway which
acts by inhibiting signaling though TGFbRI. Galunisertib
is currently being evaluated clinically in several Phase I
and II studies; as a monotherapy, galunisertib has shown
antitumor activity against a variety of tumors, including
durable and long-term responses in patients with glioma.
To explore the impact of Galunisertib monotherapy on
anti-tumor T cell immunity, we utilized murine tumor
models. Treatment of mice with well-established 4T1-LP
(poorly immunogenic 4T1 breast tumor engineered to
express luciferase) implanted in the mammary fat pad
resulted in strong dose-dependent anti-tumor activity with
nearly 100% inhibition of tumor growth across doses dur-
ing the dosing period, with complete tumor responses
upon cessation of treatment in ~50% of animals at the
highest dose tested; depletion studies demonstrated that
regression of 4T1-LP was dependent on the presence of
CD8+ T cells. Rechallenge of treated, tumor free mice
resulted in complete rejection of 4T1-LP tumor cells but
no rejection of EMT6-LM2 tumor cells, demonstrating the
establishment of a durable response and immunological
memory. Treatment of mice bearing established parental
4T1 tumors in the mammary fat pad resulted in no signifi-
cant inhibition of tumor growth, indicating that the pre-
sence of a foreign antigen (i.e. LP), potentially enhanced
the ability to regress the 4T1-LP derivative. Animals that
rejected the immunogenic 4T1-LP tumors were able to
also reject 4T1 parental cells upon rechallenge, suggesting
the development of a secondary immune response via
antigen spreading as a consequence of effective tumor tar-
geting. In the CT26 murine colon carcinoma model, treat-
ment of established tumors with galunisertib or anti-PD-L1
as monotherapies resulted in tumor growth inhibition
compared to control of 75% and 86%, respectively (T/C
values of 25% and 14%); complete responders were
observed in about 20% of treated animals in both mono-
therapy groups. Combination of galunisertib with anti-PD-
L1 resulted in an enhanced tumor growth inhibition of
98% (T/C value of ~2%), and a complete response rate of
~50%, suggesting at least additive activity with potential for
synergy when targeting the TGFb and PD-1 pathways.
Taken together, these data demonstrate the potential for
galunisertib treatment to enhance the development of anti-
tumor T cell immunity, which can be enhanced by combi-
nations with immune check point inhibitors.
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